The Health Resources and Services Administration (HRSA) submitted guidance on the 340B Drug Pricing Program to the Office of Management and Budget (OMB) last week for review.  OMB’s website reflects that the proposed rule was received on May 6.  The document is expected to address key policy issues raised by the various stakeholders committed to the integrity of the 340B Program.  For additional information regarding the anticipated scope of the proposed omnibus guidance, please see our February 16, 2015 Health Headline, available by clicking here.